Why the study?
Patients with CKD have elevated risks of both thromboembolism and bleeding, but specialized risk-assessment scales accounting for CKD features are lacking.
The paper highlights the need for specialized risk scales to accurately assess thromboembolic and bleeding risks in patients with chronic kidney disease.
Clinicians should apply standard scores cautiously in CKD; leaves open validation of dedicated thromboembolic and bleeding scales.
Chronic kidney disease (CKD) is a global health problem. Patients with CKD have an increased risk of thromboembolic complications and bleeding. It remains difficult to determine the benefits and risks of antiplatelet and anticoagulant therapy in patients with CKD, so an individualized risk assessment of each patient should be mandatory. To date, there are no specialized scales for assessing the risk of thromboembolic events and bleeding, which are focused on patients with CKD and take into account all the features of the course of CKD and the specific factors of their occurrence. In this work, we decided to conduct a detailed assessment of the accuracy of the currently accepted risk scales for thromboembolic events and bleeding in patients with CKD.
No takes yet. Share an insight, caveat, or question.
Mykhaloiko et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: